The top 20 pharmaceutical companies have implemented a raft of new initiatives in the last two years. Yet in two important areas, progress remains static.

› Go to Key Findings

The industry pipeline is concentrated on five diseases. Five companies are developing more than half the products for developing countries.

› Go to Key Findings

Half of the companies in the Index are developing medicines tailored for children, with 7% of the overall research pipeline being devoted to “child-size” medicine.

› Go to Key Findings

More companies are tailoring their prices to different segments of national populations.

› Go to Key Findings



Download the report

Download the report

2014 Index Ranking

Latest News

2015 Methodology Review: independent experts meet to evaluate next Index methodology

16 June 2015 |
On 17 June, the Expert Review Committee will gather in Haarlem to review key methodology proposals for the next Access to Medicine Index and the first Access to Vaccines Index.› Read more

Catch-up: How do pharma companies support MDG5?

24 June 2015 |
Catch-up with the web discussion co-convened by the Access to Medicine Foundation, the UN Foundation and Family Planning 2020 about how pharmaceutical companies’ are improving access to maternal health and contraception. The discussion centers on a landscape study recently published by the Access to Medicine Foundation. › Read more

2015 Methodology Review: targeting key aspects of the Index analysis

13 May 2015 |
The Access to Medicine Foundation is now reviewing the Index methodology in preparation for the next Access to Medicine Index. With stakeholder engagement as a central pillar, the 2015 Methodology Review focuses on key aspects of the Index analysis. › Read more

Access to Vaccines Index: introducing the first principles

12 May 2015 |
The Access to Medicine Foundation has started the development of a new Index, focused exclusively on vaccines. It will measure and compare the efforts of vaccine manufacturers to make vaccines accessible for people living in developing countries.› Read more

New Research: How pharmaceutical companies address access to maternal and reproductive health

9 April 2015 |
Every day, an estimated 800 women die during pregnancy and childbirth due to preventable causes. Today, the Access to Medicine Foundation publishes the first landscape study of pharmaceutical companies’ responses to MDG 5 to help improve this situation.› Read more

What Leaders Say

Dr. Margaret Chan
Director-General, World Health Organization
"The Access to Medicine Index is a very important project. What gets measured, gets done."
Bill Gates
Chairman of Microsoft Corporation, Co-Chair and Trustee of the Bill & Melinda Gates Foundation
"When I talk to executives from pharmaceutical companies they tell me that they want to do more for neglected diseases, but they at least need to get credit for it. The Access to Medicine Index does exactly that."
Justine Greening
Justine Greening
The Rt Hon Justine Greening MP, Secretary of State for International Development, UK
This year’s index shows that the pharmaceutical industry has made progress in improving access to vital medicines for the globe’s poorest people, helping to tackle some of the world’s worst diseases. The deadly Ebola outbreak reminds us that there is still much to be done to stop the spread of diseases in developing countries.
Lilianne Ploumen
Minister for Foreign Trade and Development Cooperation, the Netherlands
“The Access to Medicine Index mobilizes the strength of the private sector, impacting the lives of millions of the most vulnerable people on earth. It showcases the synergy of aid, trade and investment.”
Knut Kjaer
Former CEO of RiskMetrics Group, Former CEO of Norges Bank Investment Management (NBIM) (1997-2007)
"Companies are beginning to understand that the value of corporate social responsibility programmes is not only the opportunity to do the right thing but that it's good for business as well. The Access to Medicine Index provides companies with a chance to improve performance and explore new business models while helping societies in need."

In the Media

Findings from 2014 Access to Medicine Index in the Guardian

26 June 2015 |

The Guardian looks at whether pharmaceutical companies are changing their business approach in low and middle income countries, drawing on findings on pricing practices from the 2014 Access to Medicine Index.

› Read more

ESG Matters from Allianz Global Investors references the Index

27 May 2015 |

In an article about Access to Medicine Strategies, the Access to Medicine Index is cited as a source of insight into pharmaceutical company performances on access to medicine.

› Read more

UN Special covers the 2014 Access to Medicine Index

27 May 2015 |

Danny Edwards sets out the main findings of the 2014 Access to Medicine Index in the UN's in-house magazine.

› Read more

Jay Iyer on Danish pharma companies in Politiken

19 April 2015 |

Danish newspaper Politiken publishes a piece by Jayasree K. Iyer, the Index's Head of Research, and Damiano de Felice, Strategy.

› Read more

Jay Iyer on Swiss Index companies in Le Temps

12 March 2015 |

Writing in Le Temps, Index team members Damiano de Felice and Jayasree K. Iyer (Head of Research) give an overview of how Swiss policy and Swiss pharmaceutical companies are addressing access to medicine.

› Read more